SCHEMBL2881081

SCHEMBL2881081

Fc1cc(F)cc(N(Cc2ccccc2)Cc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.52
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
TSHR P16473 4/20 0.48
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
NR3C1 P04150 1/20 0.45
PTPN1 P18031 1/20 0.44
CETP P11597 2/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP2D6 P10635 2/20 0.41
TAAR1 Q96RJ0 2/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
PDE6A P16499 1/20 0.41
ADRA2C P18825 1/20 0.41
MC4R P32245 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9809629 0.86 CRHBP (0.56) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL16416625 0.83 CRHBP (0.43) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL16412351 0.83 CYP2C19 (0.41) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL16412580 0.81 CRHBP (0.55) CYP2C19CRHBPCRHR2TSHRNR3C1
SCHEMBL15122530 0.81 NR1H2 (0.49) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL10974928 0.80 CRHBP (0.68) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL19212236 0.80 NR1H2 (0.49) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL30910363 0.79 CRHBP (0.43) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL12346186 0.79 CYP2C19 (0.56) CYP2C19CRHBPCRHR2TSHRNR1H2
SCHEMBL13322100 0.79 CYP2C19 (0.47) CYP2C19CRHBPCRHR2TSHRNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 CYP2C19 238/4885CRHBP 3827/4885CRHR2 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.